rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
1
|
pubmed:dateCreated |
2009-12-16
|
pubmed:abstractText |
Type 2 diabetes is a progressive disease for which current treatments are often unsatisfactory with respect to achieving therapeutic goals and unwanted side effects. AREAS COVERED: Preclinical and clinical studies of linagliptin, a new oral antidiabetic agent, including data presented at Scientific Meetings and peer-reviewed studies published since 2007.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
1744-7658
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:volume |
19
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
133-40
|
pubmed:dateRevised |
2011-11-17
|
pubmed:meshHeading |
pubmed-meshheading:19947894-Animals,
pubmed-meshheading:19947894-Clinical Trials as Topic,
pubmed-meshheading:19947894-Diabetes Mellitus, Type 2,
pubmed-meshheading:19947894-Dipeptidyl-Peptidase IV Inhibitors,
pubmed-meshheading:19947894-Drug Evaluation, Preclinical,
pubmed-meshheading:19947894-Humans,
pubmed-meshheading:19947894-Hypoglycemic Agents,
pubmed-meshheading:19947894-Molecular Structure,
pubmed-meshheading:19947894-Purines,
pubmed-meshheading:19947894-Quinazolines,
pubmed-meshheading:19947894-Xanthine
|
pubmed:year |
2010
|
pubmed:articleTitle |
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes.
|
pubmed:affiliation |
University of Copenhagen, Panum Institute, Department of Biomedical Sciences, DK-2200 Copenhagen N, Denmark. deacon@mfi.ku.dk
|
pubmed:publicationType |
Journal Article,
Review,
Research Support, Non-U.S. Gov't
|